Bruker Corporation (NASDAQ: BRKR) and Derma Sciences (NASDAQ:DSCI) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Bruker Corporation and Derma Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bruker Corporation 2 9 3 0 2.07
Derma Sciences 0 1 0 0 2.00

Bruker Corporation currently has a consensus target price of $28.90, indicating a potential downside of 17.78%. Given Bruker Corporation’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Bruker Corporation is more favorable than Derma Sciences.

Earnings & Valuation

This table compares Bruker Corporation and Derma Sciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Bruker Corporation $1.61 billion 3.39 $153.60 million $0.94 37.39
Derma Sciences N/A N/A N/A ($0.31) -22.58

Bruker Corporation has higher revenue and earnings than Derma Sciences. Derma Sciences is trading at a lower price-to-earnings ratio than Bruker Corporation, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bruker Corporation and Derma Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bruker Corporation 8.85% 25.83% 10.05%
Derma Sciences -20.97% -17.10% -12.43%

Insider & Institutional Ownership

66.3% of Bruker Corporation shares are owned by institutional investors. Comparatively, 58.9% of Derma Sciences shares are owned by institutional investors. 35.2% of Bruker Corporation shares are owned by company insiders. Comparatively, 9.9% of Derma Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dividends

Bruker Corporation pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Derma Sciences does not pay a dividend. Bruker Corporation pays out 17.0% of its earnings in the form of a dividend.

Summary

Bruker Corporation beats Derma Sciences on 11 of the 12 factors compared between the two stocks.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, manufactures and distributes enabling life science tools. The Bruker CALID segment designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive detection products. The Bruker Nano segment designs, manufactures and distributes spectroscopy and microscopy instruments. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices. It also focuses on nanomechanical testing instruments.

About Derma Sciences

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company’s traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.